Cellular studies
Results from the clinical trials demonstrated the beneficial effect of
MR antagonism in HFrEF and in HFpEF. MRA therapy could improve cardiac
function, and reduce cardiac hypertrophy, inflammation, fibrosis,
arterial stiffness or endothelial dysfunction. Already after the
publication of the RALES study in 1999, in parallel to the subsequent
clinical studies with MRA, the markedly beneficial results led
researchers to perform numerous basic and translational studies focusing
on the analysis of MR expression and activation in cells of the CV
system.